Dyslipidaemia is often associated with hypertension, and many clinical trials have shown that lipid-lowering therapy and strict blood pressure (BP) control are important for preventing cardiovascular disease (CVD). However, few reports describe the effect of statins on CVD occurrence in relation to long-term BP control. In the present analysis, we investigated the effects of baseline BP and follow-up BP control on the occurrence of CVD in patients enrolled in the MEGA Study. We investigated whether BP values provide more accurate prediction of the occurrence of CVD, including cerebrovascular disease/ transischemic attack (CVA/TIA), and the effect of pravastatin on CVA/TIA. The risk for CVA/TIA and other CVD increased significantly (Pp0.001) as the severity of hypertension increased. In contrast, pravastatin reduced the onset of CVA/TIA, regardless of the BP controlled. The mean BP was a more accurate predictor of CVD than a one-time BP value. In patients with mildto-moderate dyslipidaemia, elevated BP increases the risk for CVA/TIA and other CVD, and rigorous BP control was important for preventing CVD, in particular CVA/TIA. The 12-month mean BP is useful to avoid attenuation to determine the association between CVD and BP. Pravastatin prevented CVA/TIA, regardless of BP controlled.
Introduction
Hypertension was shown to be a risk factor for cardiovascular events in the Framingham Heart Study and many other cohort studies. [1] [2] [3] [4] [5] [6] In addition, dyslipidaemia is a conventional risk factor for cardiovascular disease (CVD), and the presence of hypertension increases the incidence of CVD. [7] [8] [9] We previously reported that hypertension is a strong risk factor for coronary heart disease (CHD) 10 and stroke, 11 and that pravastatin is effective to prevent cardiovascular events in patients with hypertension in the MEGA Study. 12 Guidelines for the treatment of hypertension have been formulated by groups in various countries across the globe, and include the US Joint National Committee, 13 World Health Organization/International Society of Hypertension 2003, 14 European Society of Hypertension (ESH)-European Society of Cardiology (ESC) 2007 15 and Japanese Society of Hypertension (JSH) 2009. 16 These guidelines universally recommend a treatment plan based on evaluation of CVD risk factors. They also recommend that blood pressure (BP) be strictly controlled on a 24-h basis by evaluating values of home BP monitoring and/or ambulatory BP monitoring. However, most of the previous studies that evaluated the association between BP values and CVD in patients with dyslipidaemia used BP values during the observation period or at the start or end of the study period, rather than values during the study period. Therefore, we conducted a post-hoc analysis to investigate the influence of BP control in patients with dyslipidaemia in relation to follow-up BP control status and to baseline BP levels. Additionally, we determined the effect of pravastatin on cerebrovascular disease/transischemic attack (CVA/ TIA) in relation to follow-up BP control status.
As BP fluctuates considerably in individual patients, it could weaken the association when the relationship with events is investigated, a phenomenon known as attenuation. 17 Therefore, we used two methods in this study for the evaluation of follow-up BP measurements, one involving the time nearest to occurrence of the event and the other using the mean value for the 12 months before the event. We investigated the relationship between BP measurements using these methods and event occurrence to evaluate the appropriateness of BP values for more accurately predicting event occurrence. In addition, we investigated the effects of BP control on the occurrence of CVA/TIA under treatment with pravastatin.
Patients and methods
The design and overall results of the MEGA Study have been reported previously. 18 A brief overview is provided here. The MEGA Study, a prospective, randomized, open, blinded end-point study (PROBE design) was carried out from February 1995 to March 2000. The subjects were men and postmenopausal women aged 40-70 years with hypercholesterolaemia and no history of CHD or cerebrovascular disease. The exclusion criteria were familial hypercholesterolaemia, a history of CVD, malignancy and secondary hyperlipidaemia. Informed consent to participate in the study was obtained in writing. Two to three times over a 12-week period, serum cholesterol levels were measured in accordance with the standardized method recommended by the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA). Subjects with total cholesterol (TC) levels of 5.69-6.98 mmol l À1 were stratified according to sex, age and medical institution, and randomly assigned to diet alone, or diet plus pravastatin, using the permuted-block method. At each visit, the attending physician evaluated patients, with each receiving a medical check-up that included BP measurement and determination of the onset of endpoints at 1, 3 and 6 months after the start of follow-up, and every 6 months thereafter, and electrocardiography performed once a year. Patient data were recorded on case report forms by attending physicians and reported to the data centre. Events were diagnosed by the attending physician in accordance with the MEGA Study assessment criteria and reported in detail. For each reported event, the Endpoint Committee (event assessment committee) obtained detailed information from physicians and evaluated the event under blinded conditions in accordance with previously described criteria. During the study period, TC, high-density lipoprotein cholesterol, triglyceride and lipoprotein (a) levels were measured centrally at the same laboratory using methods standardized by the CDC. Low-density lipoprotein cholesterol level was estimated by the Friedewald formula. 19 The primary composite endpoint was the first occurrence of CHD (fatal or nonfatal myocardial infarction, sudden and cardiac death, coronary revascularization procedure and angina). The secondary endpoints were stroke, CVA/TIA, CHD plus CVA/TIA, all cardiovascular events and total mortality. All events were independently evaluated under blinded conditions by the Endpoint Committee. Throughout the study period, patients in both groups were advised to follow the US National Cholesterol Education Program Step I diet. 20 Treatment in the diet plus pravastatin group was initiated at pravastatin 10 mg day À1 . During follow-up, the pravastatin dose could be uptitrated by the attending physician to 20 mg day À1 if TC did not decrease to p5.69 mmol l À1 , in accordance with the approved Japanese dose. Patients in either group with TC exceeding 6.98 mmol l À1 , even after enhancement of their assigned treatment, could be switched to other aggressive treatment, including statin therapy. Concomitant treatment for complications was not restricted in either group. The followup period was initially scheduled for 5 years, but on the recommendation of the Data and Safety Monitoring Committee, the study was continued for a further 5 years to increase the number of events observed. Hence, patients who provided written informed consent at 5 years were followed until the end of March 2004.
The study was conducted in compliance with the ethical principles of the Declaration of Helsinki and in accordance with the Japanese Ministry of Health, Labour and Welfare regulations on post-marketing surveillance. The protocol was approved by the institutional review board. Statistical analyses were performed in accordance with the intention-to-treat principle.
Data obtained for all 7832 patients were analysed at the completion of 60 months as previously reported. [10] [11] [12] 21, 22 This was done to reduce potential bias because of the greater use of statins by patients in the diet group, owing to extension of the followup period.
Investigation of the accuracy of follow-up BP control indicators
To ascertain the effects of attenuation caused by measurement error in BP values obtained during the study period (follow-up BP), we investigated the accuracy of BP control indicators. For follow-up BP, we used the measured values obtained at each clinic visit, and two approaches, indicator 1 and indicator 2, were used to assess BP control. Indicator 1 used the BP values obtained at the time point nearest the clinic visit, and indicator 2 used the mean BP over the 12-month period before and after the clinic visit ( Figure 1 ). BP was measured by auscultatory method in each patient while seated at each visit. The treatment of hypertension was at the discretion of the physician.
Using these indicators of BP control, we determined the hazard ratios (HRs) for each ESH/ESC 2007 and JSH 2009 BP category (normal, high normal, grade 1, grade 2-3) by means of the Cox proportional hazard model, with BP as the timedependent explanatory variable. The HR in each category was determined relative to normal BP as the reference group. The other adjustment factors were low-density lipoprotein cholesterol (time-dependent), treatment group, sex, age, body mass index, lipoprotein (a), diabetes and smoking. The visits for which time-dependent values were used were at 1, 3 and 6 months, and half-yearly thereafter. In the case of missed measurements, values were imputed via a linear regression model using the following covariates: treatment group, sex, age, baseline lipid levels (TC, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride), body mass index, diabetes, hypertension, history of antihyperlipidaemic treatment, smoking, alcohol consumption, the value measured at the previous visit and baseline BP (only when imputing BP values). Values obtained after event occurrence were excluded.
Relationship between BP control status and occurrence of events We examined the effect of follow-up blood control status on the occurrence of each cardiovascular event. By analysis of the above time-dependent Cox proportional hazard model using the indicator considered to be the most accurate, we ascertained the association between pre-event BP control and the onset of an event. The events analysed were CVA/TIA, CHD, stroke, CHD plus CVA/TIA, CVD, and total mortality. HRs were determined for followup mean BP classified according to the ESH/ESC 2007 and JSH 2009 severity criteria, and for increase in systolic blood pressure (SBP) and diastolic blood pressure (DBP) by 10 mm Hg and 5 mm Hg, respectively.
Effects of BP control and pravastatin on the occurrence of CVA/TIA To determine the effects of BP control and pravastatin on the occurrence of CVA/TIA, we examined the effects of BP control in the diet group and the diet plus pravastatin group. Using normal BP as the reference group for baseline BP and follow-up BP in the diet group, we determined the HR for use of pravastatin according to the BP category at baseline and during the study. The HR was calculated as a time-dependent covariate in a Cox regression model with adjustment for gender, age, high-density lipoprotein cholesterol, history of diabetes, and baseline smoking.
Given their smaller numbers, patients in grade 1 and grade 2-3 are reported together.
Results
The baseline and follow-up period clinical characteristics of the 7832 subjects in the study are shown in Table 1 . About 40% of the patients had hypertension and were taking antihypertensive drugs at both baseline and follow-up period. The mean BPs were unchanged throughout the follow-up study.
Effect of attenuation due to BP measurement error
We investigated the effect of attenuation on the association between the onset of CVA/TIA and BP values. For indicator 1, the HR for the incidence of CVA/TIA for each BP category, compared with normal BP, was 2.05 for high normal, 2.63 for grade 1, and 3.18 for grade 2-3, using the JSH classification. For indicator 2, however, the HR was significantly higher for each BP category (3.41, 5.02 and 8.80, respectively; Figure 2 ). This suggests that attenuation potentially occurs for the BP values at the time point immediately before event occurrence, and that the 12-month mean should be used to avoid attenuation when determining the association between subsequent events and BP. Based on this finding, indicator 2 (12-month mean) was used to define BP control status in the following analyses.
Association between BP control status and the occurrence of events For CHD, the risk was elevated for BP levels in the ESH/ESC 2007 and JSH 2009 category of grade 2-3 hypertension only, with an HR of 2.07 (P ¼ 0.0487). In contrast, the HR for CVA/TIA by BP severity was 3.47 (P ¼ 0.0027) for high normal, 5.13 for grade 1 (Po0.0001) and 9.07 (Po0.0001) for grade 2-3, showing that the risk was significantly higher for each increase in severity of hypertension. For CVD, there was a similar increase in risk in relation to worsening BP control; however, the increase was about one-half that for CVA/TIA (HR 1.60 (P ¼ 0.0047) for high normal, 1.72 for grade 1 (Po0.001) and 2.99 (Po0.0001) for grade 2-3). For total mortality, no consistent trend was seen between the BP categories ( Figure 3) .
A 10 mm Hg increase in SBP significantly increased the risk of CVA/TIA by 48% and CVD by 22%, and a 5 mm Hg increase in DBP significantly increased these risks by 27 and 15%, respectively (Po0.001 for all; Figure 4 ). However, no association was seen for CHD.
Effects of BP control and pravastatin on the occurrence of CVA/TIA CVA/TIA events were observed in 70 patients during the 5-year follow-up period (1.98 per 1000 person years).
In both the diet group and the diet plus pravastatin group, the risk of CVA/TIA was higher with worsening of follow-up BP control, regardless of the In the diet group, the risk for CVA/TIA was significantly greater compared with the diet plus pravastatin group. Notably in the diet group, there was a linear increase in risk for CVA/TIA as BP worsened from baseline to the next higher grade of BP (Table 2 ). In the normal BP group at baseline, when BP worsened to grade 1-3 at follow-up, the HR for CVA/TIA was 8.64 (P ¼ 0.019). In the high normal group at baseline, the HR was 6.93 for grade 1-3 (P ¼ 0.009), and it was 8.64 in the grade 1-3 group at baseline ( Table 2 ).
The incidence of CVA/TIA in the patients with good BP control was about one-half lower than in the patients with poor BP control in both the diet only and diet plus pravastatin groups (Table 3) . Therefore, BP control was equally as important as treatment with pravastatin to prevent CVA/TIA in patients with dyslipidaemia.
Discussion
High BP was shown to be a strong risk factor for cardiovascular events in epidemiological studies, [5] [6] [7] including the Framingham Study [1] [2] [3] and MRFIT. 4 It is well known that the accumulation of risk factors for cardiovascular events increases the incidence of such events. In previously reported subanalyses of the MEGA Study involving patients with hypertension and diabetes, the incidence of cardiovascular events was higher than in patients without hypertension and diabetes. 12, 22 The guidelines for the treatment of hypertension emphasize a lower goal BP level for high-risk patients, including those with dyslipidaemia, than for low-risk For both baseline blood pressure and follow-up blood pressure in the diet group, the hazard ratio for CVA/TIA in each category based on changes from baseline blood pressure to follow-up blood pressure are displayed for each treatment group, compared with the normal blood pressure group. The hazard ratio was calculated as a time-dependent covariate in a Cox regression model with adjustment for gender, age, high-density lipoprotein cholesterol, history of diabetes and baseline smoking. Blood pressure control was defined as good when on-treatment BP was equal to or better than baseline BP. BP control was defined as poor when on-treatment BP was worse than baseline BP. 
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The present study showed that the greater the increase in follow-up SBP or DBP, the higher the incidence of resulting cardiovascular events, in particular CVA/TIA and stroke, reconfirming the importance of BP control in patients with dyslipidaemia too. Also, assessment of BP status not only at baseline but also during the follow-up period is important partly because adherence to antihypertensive therapy in patients with dyslipidaemia is not as good as one might expect. 23 BP levels fluctuate in individual patients. Circadian variations, physical and mental conditions when visiting the clinic, and measurement errors can influence BP levels. When examining the association between the onset of events and BP data that may include such measurement errors, it is necessary to correct the data for attenuation. To reduce the bias caused by attenuation from multiple BP measurements, MacMahon and colleagues 24 recommended determining a mean value for a suitable period. Our present study confirms that the multiple-measurement technique for BP values yields a more accurate picture of risk for predicting the onset of CVA/TIA. Furthermore, in evaluations of the antihypertensive effects via short-term BP measurements in routine practice, Keenan et al. 25 identified the possibility that changes in BP may be erroneously assessed. Therefore, it appears important to control BP values by periodically obtaining multiple BP measurements when evaluating BP for risk assessment, having regard for the variations that may occur.
Interestingly, concomitant statin therapy has been shown to prevent CVD events in patients without hypertension or dyslipidaemia, thereby broadening the population who will benefit from such therapy, according to recently published reports. The AS-COT-LLA trial, 26 a large-scale clinical study that examined the ability of combined antihypertensive plus statin therapy to reduce cardiovascular events in hypertensive patients with normal cholesterol levels (p6.5 mmol l À1 ), showed a significant 21% reduction in cardiovascular events with the addition of a statin. 26, 27 Further, statins were shown to reduce the incidence of events in the MRC/BHF Heart Protection Study, a large-scale study in high-risk patients with coronary disease or other occlusive arterial disease or diabetes with normal cholesterol levels (X3.5 mmol l À1 ). 28 The results of the present study indicate that BP control during the follow-up period is important to reduce the onset of cardiovascular events, particularly CVA/TIA, in patients with dyslipidaemia with moderate cholesterol levels (5.69-6.98 mmol l À1 ). Further, it appears from our results that pravastatin reduces the onset of CVA/TIA, regardless of whether or not BP control is good.
The ACCORD study indicated that targeting a SBP of o120 mm Hg, as compared with o140 mm Hg, did not lower the cardiac event rate but reduced stroke risk. 29 In countries such as Japan, in which the prevalence of stroke is higher than that of coronary diseases, strict BP control status may improve total cardiovascular risk.
Regarding CVA/TIA, for which the association with BP control was strongest, we found that the incidence of CVA/TIA increased in both the diet group and the diet plus pravastatin group as BP control worsened during follow-up. However, the size of the increase was smaller in the diet plus pravastatin group, showing that pravastatin contributed to the reduction in CVA/TIA independent of BP control ( Table 2 ). This analysis indicated that rigorous BP control with statin therapy appears to be important for preventing CVA/TIA. On the other hand, the PROSPER trial did not show an effect on stroke with a statin. It seems that this lack of effect in PROSPER is in part due to the higher number of patients with hypertension (59% of men, 80% of women) and the higher baseline levels of SBP compared with other statin studies (155 mm Hg vs about 140 mm Hg). 30 This reinforces the importance of BP control for preventing CVD and CVA/TIA in particular. On the other hand, no correlation was shown between BP levels and total mortality in the present analysis, although this is likely because of the small number of patients and short follow-up period. Although there are few reports of the relationship between BP and total mortality in Japanese patients, the EPOCH-JAPAN 31 meta-analysis of 13 cohort studies in Japanese patients had the power to show that high BP raised the risk of total mortality.
The results from the present study suggest that statin therapy should be started in hypertensive and high-risk patients regardless of their low-density lipoprotein cholesterol values.
The MEGA Study was not intended to evaluate BP control, therefore there were no strict BP control regulations, and the diagnosis of hypertension and its treatment were left to the physician's discretion. Therefore, although BP levels and the use of antihypertensive medications were similar in the diet group and the diet plus pravastatin group, there may be a limitation in relation to BP control. In addition, the lower incidence of CVD compared with western countries may be a limitation.
Prospective data are needed to support the findings from this post-hoc analysis of the MEGA Study regarding the relation between BP control and pravastatin.
Conclusions
We confirmed that BP control in patients with dyslipidaemia is important for reducing the onset of cardiovascular events, in particular to reduce the incidence of CVA/TIA. We confirmed that multiple measurements of BP during follow-up yield a more accurate picture of risk for predicting the onset of CVA/TIA than baseline BP.
It also appears that pravastatin reduces the onset of CVA/TIA, regardless of whether or not BP control is good. Pravastatin combined with good BP control in patients with dyslipidaemia is important for preventing cardiovascular events, and in particular for reducing the incidence of CVA/TIA.
